Altura™ Endograft System Granted CFDA Green-Path

On December 6, Altura™ Endograft System ("Altura™"), distributed by MicroPort Endovascular (Shanghai) Co., Ltd. ("MicroPort*Endovascular") and developed by UK-based Lombard Medical, Inc. ("Lombard Medical"), was granted to enter the special Green-Path by China Food and Drug Administration ("CFDA"), which is rapid-track of review and approval procedure for innovative medical devices.

Altura™ is the world’s first and only device boldly and effectively evolving the conventional bifurcated main body into unique Bilateral D-Stent Design, with ultra-low profile of 14F. The unique Bilateral D-Stent Design of Altura™ enables the offset aortic endografts to be independently positioned, maximizing seal in infrarenal neck. Besides, the proximal portion of the aortic endografts with the design of uncovered suprarenal bare stent and active anchor fixation minimizes the occurrence rate of complications of endoleak and stent migration, to provide a simple, reliable solution for physicians in the treatment of AAA. Previously, the Altura™ system received CE Mark in 2015.
MSC Hosts Product Launch of Rega™ Family Implantable Pacemakers

On December 22, MicroPort Sorin CRM (Shanghai) Co., Ltd. ("MSC"), a joint venture of MicroPort®, attended the 10th China International Pacemaker Summit ("CIPS") and hosted product launch of Rega™ Family Implantable Pacemakers with renowned pacemaker professionals in attendance. As the first domestically made world-class pacemakers in China, the official launch of Rega™ Family Implantable Pacemakers marks a milestone in the development of China’s own pacemakers, which is expected to benefit a large group of domestic patients with its high quality and affordable price.

In September 2017, MicroPort® announced the approval of China Food and Drug Administration ("CFDA") for its Rega™ Family Implantable Pacemakers, making them the first domestically made world-class pacemakers in China. Rega™ Family Implantable Pacemakers has three series (Orchidee™, Trefle™, and Rega™) with a total of eight models. They are all automatic, physiologic pacing pacemaker devices that feature disease management, small size and long life span. Specifically, they are the smallest pacemakers available in market with only eight cubic centimeters in volume, and they have service life of 10 to 12 years, allowing them to meet the need of various patients.

Currently, implanting pacemakers is the only effective way to reduce mortality and improve life quality of patients with bradycardia. There are around one million patients suffering from bradycardia in China with an estimated 300,000 to 400,000 new cases annually. However, due to lack of core technologies and industrialization experience, China almost solely relies on imports for pacemaker devices, the high price of which has deterred most patients with only 80,000 of them can be treated with pacemakers each year. After this product launch, Rega™ Family Implantable Pacemakers had been put into clinical use. Dr. Li Wang, Chief Executive Officer of MSC and Fellow of Heart Rhythm Society, said: "With world-class quality and affordable price, it is expected that these pacemaker devices can provide safe, efficacious and cost-effective high-end solutions and service to physicians to help improve the life quality for more domestic patients in China."

In November 2017, MicroPort® announced that the company will acquire LivaNova’s Cardiac Rhythm Management ("CRM") Business Franchise for $190 million in cash. The transition is expected to be completed by the second quarter of 2018. Upon completion of the acquisition, MicroPort® will become the most advanced domestic company in China with CRM know-how in the global CRM market which is estimated to be $10 billion. This acquisition will transform the domestically made pacemakers from a market follower to a potential competitor to market top leaders. Based on the success of LivaNova’s world-class CRM devices, MicroPort® will continue to develop innovative CRM devices for the China market with tailor-made treatment and service, to better serve the domestic patients.
MicroPort® Attends CBS 2017

MicroPort® attended the 10th Left Main & Coronary Bifurcation Summit ("CBS 2017") held in Nanjing of Jiangsu Province, and had in-depth communication with several overseas experts. During the conference, the physicians spoke highly of the excellent crossability, pushability of Firehawk® Rapamycin Target Eluting Coronary Stent System ("Firehawk®"). Taking the opportunity of this summit, Dr. Ricardo Alves Da Costa, Dr. Pierfrancesco Agostoni, and Dr. Koen Teeuwen were invited to visit MicroPort® and MicroPort® Self-Experience Center. They said they were impressed by the incredible innovation ability and diversified business of MicroPort®.
MicroPort® CardioFlow Attends 2017 PCR-CIT China Chengdu Valves

On November 25, MicroPort Shanghai CardioFlow Medtech Co., Ltd. ("MicroPort® CardioFlow") attended the 2017 PCR-CIT China Chengdu Valves and displayed its VitaFlow™ Transcatheter Aortic Valve and Delivery System ("VitaFlow™"). The conference was hosted by PCR, CIT, and Huaxi Hospital of Sichuan University.

In the session of transcatheter aortic valve innovative treatment, the representative of MicroPort® CardioFlow delivered a speech about "Innovative Solution of MicroPort*: to Solve the Unmet needs," sharing MicroPort® CardioFlow's understanding in the unmet needs and proposed solutions. According to the speech, there are three keys factors in technical improvement of TAVI treatment: reducing the occurrence rate of postoperative complications, solving the clinical challenges in special anatomic conditions, and ensuring the long-term efficacy. With its innovative skirt design, VitaFlow™ can effectively reduce the paravalvular leak. It keeps its outer diameter at 16F/18F while reinforcing its radial force, which can skillfully expand calcified leaflets. The excellent clinical outcome of VitaFlow™ has won recognition from industry peers. Moreover, the device has achieved breakthrough in coping with bicuspid aortic valve challenge - there has no significant difference of clinical results between 41 bicuspid aortic valve patients (41/110) and other non-bicuspid patients who are enrolled in Chinese FDA clinical trial. Afterwards, MicroPort® CardioFlow introduced the upcoming second-generation of VitaFlow™. Its added recapturable function will greatly lower the difficulty of positioning during the procedure, which effectively improve the success rate and facilitate physicians in operation. The second generation of VitaFlow™ product has many features including direct access, omnidirectional navigation, and reinforced compatibility which would help reduce vascular complication remarkably. In the end, the representative of MicroPort® CardioFlow presented on the development trend of future products. MicroPort® CardioFlow will continue to innovate and increase product offerings based on the unmet clinical needs to provide comprehensive solutions for physicians.
MicroPort® NeuroTech Attends CINS 2017

MicroPort NeuroTech (Shanghai) Co., Ltd. ("MicroPort® NeuroTech") recently attended the 3rd Annual Conference of Chinese Interventional Neuroradiology Society of Chinese Stroke Association ("CINS 2017").

The opening speech was chaired by Professor Xinjian Yang of Beijing Tiantan Hospital. Professor Zhongrong Miao, Chairman of the CINS 2017, delivered the opening speech in which he showed his determination to learn from the hard-work spirit of neurointerventional experts to contribute to the development of China's neurointerventional industry. Professor Zhongxue Wu of Beijing Tiantan Hospital expressed his expectation on behalf of senior neurointentional professionals, encouraging the experts in attendance to find better solutions for the treatment of stroke with joint efforts.

During the congress, Professor Liangfu Zhu of Henan Provincial People's Hospital delivered a speech of the application of balloon dilation stent in acute artery occlusion, in which he shared his clinical experience in APOLLO Intracranial Stent System ("APOLLO") and had in-depth discussion with experts in attendance. Professor Zhu analyzed the advantages of APOLLO with high recognition in its safety and efficacy. He also shared the tips and tricks in using the device.
MicroPort® Lifesciences Attends CDS2017

Shanghai MicroPort Lifesciences Co., Ltd. ("MicroPort® Lifesciences") attended the 21th Scientific Meeting of the Chinese Diabetes Society ("CDS2017") and displayed its La Fenice® Hypophyseal Hormone Infusion Pump and La Fenice® Insulin Pump in its booth.

During the conference, President of Chinese Endocrinologist Association Guang Ning of Shanghai Ruijin Hospital said, La Fenice® Hypophyseal Hormone Infusion Pump not only has good effect on the treatment of Idiopathic hypogonadotropic hypogonadism ("IHH") but also could help diagnose and treat idiopathic central secondary amenorrhea, and regulate menstrual cycles and boost the chance of pregnancy for patients with non-obesity polycystic ovarian syndrome ("PCOS").

Equipped with pulsatile infusion via micro pump technology, La Fenice® Hypophyseal Hormone Infusion Pump works as an artificial hypothalamus – it stimulates hypophysis to excrete follicle-stimulating hormone ("FSH") or luteinizing hormone ("LH") by simulating pulsatile excretion of GnRH in order to make patients recover from abnormally physiological adjustment function. It is the first domestically developed GnRH pulsatile pump. Since its market launch, a total of 134 babies were born with the help of La Fenice® Hypophyseal Hormone Infusion Pump.
MicroPort® Orthopedics Holds the Third TKA Training Course in Hong Kong

MicroPort® Orthopedics hosted the third training course regarding total knee arthroplasty ("TKA") surgical technique in Queen Mary Hospital of the University of Hong Kong. A total of 13 knee replacement experts attended the course to get a deeper understanding in the medial-pivot knee and exchange ideas on surgical techniques, blood management, pain management, and postoperative recovery.

As one of the well-known knee systems in the world, EVOLUTION® has gained high market recognition after it was launched in the US in 2010, later sold to Europe and Japan, and entered the Chinese mainland market and the Hong Kong market in 2015. According to a study evaluating long-term clinical and radiographic outcomes of the medial pivot knee system published in The Knee, the results demonstrate excellent clinical outcomes for both satisfaction (95%) and survivorship (98.8%) at 17 years with patients noting a great sense of stability and comfort during regular activities.
MicroPort® Selected as
"2017 China Innovative Medical Device Company"

On December 17, MicroPort® was selected as "2017 China Innovative Medical Device Company" during the 10th China Pharmaceutical Strategy Summit 2017. MicroPort® Chief Operation Officer Glendy Wang accepted the award on behalf of the company and delivered a report of MicroPort®’s Innovation Path during the conference. Hosted by China National Pharmaceutical Industry Information Center, China Association of Pharmaceutical Commence, and Chongqing bio-pharmaceutical Industrial Park, China Pharmaceutical Strategy Summit is a premier conference in China’s pharmaceutical industry, which provides an open platform for domestic healthcare companies to exchange ideas on innovation achievements and innovation management annually.
MicroPort® Awarded "2017 China Intellectual Property Model Enterprise"

MicroPort® was recently awarded "2017 China Intellectual Property Model Enterprise" by the State Intellectual Property Office ("SIPO"). According to information released on the website of SIPO, a total of 182 enterprises received such honor and only six are located in Shanghai. MicroPort is the only Shanghai-based medical company that made the list this year.
For more information, please contact:

**Martin Sun**
Chief Financial Officer
MicroPort Scientific Corporation
Tel: (86)(21) 38954600
Email: ir@microport.com

**Leanne Li**
Board Secretary & VP of Corporate General Affairs
MicroPort Scientific Corporation
Tel: (86)(21) 38954600
Email: ir@microport.com